Gilead Sciences Statement on Sustaining Access to AmBisome® in Low- and Middle-Income Countries

Foster City, Calif., – March 30, 2023 — Gilead Sciences, Inc. today announced that it will recalibrate the no-profit price of AmBisome^® (amphotericin B liposome for injection 50mg/vial) to governments and other non-government health organizations serving the public sector for the treatment of visceral leishmaniasis and cryptococcal meningitis in low- and middle-income countries. Gilead is making this change to ensure the long-term sustainability of AmBisome supply for the company’s global access program in these countries.

AmBisome’s current no-profit price has been in place for more than a decade, reflecting Gilead’s deep commitment to addressing neglected tropical diseases and advanced HIV-related disease in resource-limited settings. Since that time, the cost of manufacturing this complex drug and distributing it have grown substantially due to increased regulatory requirements and inflation.

Gilead recognizes the critical role AmBisome plays for patients, particularly in resource-limited countries, and made this decision to ensure the longevity of its global access program. Gilead remains committed to collaborating with governments, international organizations and local partners to work toward the goal of reducing deaths caused by visceral leishmaniasis and HIV-associated cryptococcal meningitis. Gilead’s enduring partnership with the World Health Organization has supported significant progress toward visceral leishmaniasis elimination in previously endemic regions within India, Nepal and Bangladesh. In addition, Gilead has invested in facilities to optimize manufacturing and increase production capacity. Looking ahead, Gilead will continue to support initiatives focused on strengthening health systems and delivering integrated models of care to improve the prevention, diagnosis and treatment of these diseases.

About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Forward-Looking Statements
This statement includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties, and other factors, including Gilead’s ability to maintain its global access program, including maintaining AmBisome supply under the program for low- and middle-income countries. These and other risks, uncertainties and factors are described in detail in Gilead’s Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements. 

Gilead, the Gilead logo and AmBisome are registered trademarks of Gilead Sciences, Inc.

For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.